Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Grossman
STIF
David Grossman
Stifel Nicolaus
Wall Street Analyst
★★★☆☆
#1371
on 13Foresight · ranked by our own returns
46%
Success Rate
-2.0%
Average Return
11 of 24 calls profitable · -4.5% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 46% of David Grossman's ratings turned a profit when each position was held for 1 year — averaging -2.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

83 Buy 47 Hold 0 Sell
David's Stock Coverage 19 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
PAYX
Paychex
 Jun 17, 2026 HOLD Hold
+4.9% avg upside
26 analysts
$110.00
12.03% Upside
 +0.7%
DXC
DXC Technology
 Jun 12, 2026 HOLD Hold
+231.0% avg upside
22 analysts
$12.00
39.63% Upside
 ·
HNGE
Hinge Health, Inc. Class A
 Jun 11, 2026 BUY Strong Buy
+7.5% avg upside
17 analysts
$79.00
13.88% Upside
 +0.9%
TNET
TriNet Group
 Jun 05, 2026 BUY Hold
+20.4% avg upside
12 analysts
$70.00
54.51% Upside
 -2.5%
EXLS
Exlservice Holdings
 Jun 05, 2026 BUY Strong Buy
+69.2% avg upside
13 analysts
$46.00
77.35% Upside
 ·
VEEV
Veeva Systems
 Jun 04, 2026 BUY Buy
+54.2% avg upside
36 analysts
$230.00
49.97% Upside
 -9.2%
ACN
Accenture
 Jun 03, 2026 BUY Strong Buy
+87.8% avg upside
41 analysts
$270.00
110.96% Upside
 -6.7%
IBM
International Business Machines
 May 22, 2026 BUY Buy
+0.0% avg upside
40 analysts
$290.00
16.50% Upside
 +3.4%
DRIO
DarioHealth
 May 15, 2026 BUY Strong Buy
+22.2% avg upside
5 analysts
$10.00
44.22% Upside
 ·
OPRX
OptimizeRx
 May 13, 2026 BUY Strong Buy
+158.1% avg upside
9 analysts
$14.00
181.14% Upside
 +0.6%
HCAT
Health Catalyst
 May 12, 2026 HOLD Buy
+215.1% avg upside
15 analysts
$2.00
14.89% Upside
 -19.6%
DCGO
DocGo
 May 12, 2026 BUY Buy
+415.2% avg upside
7 analysts
$2.50
377.45% Upside
 -1.7%
AMWL
American Well
 May 08, 2026 HOLD Hold
+64.5% avg upside
15 analysts
$6.50
22.84% Downside
 -5.8%
EPAM
Epam Systems
 May 08, 2026 BUY Strong Buy
+134.2% avg upside
28 analysts
$200.00
160.93% Upside
 -3.6%
ADP
Automatic Data Processing
 Apr 30, 2026 HOLD Hold
+5.1% avg upside
27 analysts
$240.00
9.98% Upside
 +3.4%
TDOC
Teladoc
 Apr 30, 2026 HOLD Buy
+257.8% avg upside
37 analysts
$5.50
31.86% Downside
 +17.0%
INFY
Infosys
 Apr 23, 2026 HOLD Buy
+84.9% avg upside
22 analysts
$15.00
41.84% Upside
 -7.6%
DH
Definitive Healthcare Corp
 Feb 27, 2026 BUY Hold
+658.6% avg upside
19 analysts
$3.00
294.76% Upside
 -33.8%
CSCO
Cisco Systems
 Aug 07, 2013 BUY Strong Buy
-27.3% avg upside
43 analysts
$58.00
51.47% Downside
 -1.8%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Grossman — Frequently Asked Questions
How accurate are David Grossman's stock ratings?
Based on the calls 13Foresight could measure, about 46% of David's ratings were profitable over a one-year hold, with an average return of -2.0% per rating, or -4.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Grossman is currently ranked #1371 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on PAYX, DXC, HNGE, TNET, EXLS, VEEV, ACN, IBM, DRIO, OPRX, HCAT, DCGO and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.